Summary:
Caspofungin, an echinocandin antifungal agent, is active against invasive Aspergillus and Candida infections. In a phase I study in healthy volunteers, mild transient increases in serum aminotransferases were observed with the concomitant administration of caspofungin and cyclosporin A (CsA). As a result, it is recommended that the concomitant use of the two drugs be limited to those settings with appropriate risk–benefit balance. We retrospectively assessed safety data in 14 patients with refractory invasive mycoses who were treated concomitantly with CsA and caspofungin before the drug was licensed in Spain. In all, 13 patients were adults (median age, 31.5 years; range, 14–67 years). The average duration of concomitant therapy was 15 days (range, 2–43 days). No clinically significant elevations of serum aminotransferases were observed, and no patient had concomitant therapy discontinued or interrupted due to a drug-related adverse event. In this study of a limited number of patients, the coadministration of caspofungin and CsA was generally well tolerated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deresinski SC, Stevens DA . Caspofungin. Clin Infect Dis 2003; 36: 1445–1457.
Maertens J, Raad I, Petrikkos G et al. Update of multicenter non-comparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). American Society for Microbiology: Washington, DC, 2002 (abstr. M-856).
Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study. N Engl J Med 2002; 347: 2020–2029.
Cancidas (caspofungin acetate). Summary of Product Characteristics. Document European Public Assessment Report, The European Agency for the Evaluation of Medicinal Products, April 2003.
Sable CA, Nguyen BYT, Chodakewitz JA, DiNubile MJ . Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25–30.
Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294–299.
Cancidas (caspofungin acetate). Scientific Discussion. European Public Assessment Report, The European Agency for the Evaluation of Medicinal Products, October 2001; Available at: http://www.eudra.org/humandocs/Humans/EPAR/caspofungin/caspofungin.htm.
Caspofungin Acetate FDA Advisory Committee Meeting Background Document. 6 December 2000; Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf.
Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
Sullivan KM . Graft vs host disease. In: Thomas ED, Blume KB, Forman SJ (eds.). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Scientific Publications: Oxford, 1999; pp 515.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Thye D, Kilfoil T, Kilfoil G, Henkel T . Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporine. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). American Society for Microbiology: Washington, DC, 2002 (abstr. A-1836).
Townsend R, Herbert M, Wisemandle W, Bekersky I . Concomitant pharmacokinetics of cyclosporine and micafungin in healthy adult volunteers. J Clin Pharmacol 2002; 42: 1051–1071 (abstr. 15).
Kaneko H, Yamato Y, Hashimoto T et al. Drug interactions of micafungin in vitro. Jpn J Chemother 2002; 50: 94–103.
White RJ, Thye D . Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society for Microbiology: Washington, DC, 2001 (abstr. A-35).
Trenschel R, Trampenau C, Elmaagacli A et al. Caspofungin (CSF) after allogeneic stem cell transplantation (SCT): a single center experience of 16 patients (pts) treated for fever of unknown origin (FUO) or invasive mycosis (IM). Bone Marrow Transplant 2002; 29 (Suppl. 2): S246 (abstr. P855).
Kartsonis N, Taylor A, Ngai A et al. Clinical experience of caspofungin and cyclosporin A in patients treated in caspofungin clinical trials. Conference Highlights – Focus on Fungal Infections. FOFI: Maui, HI, 2003 (abstr. 39).
Marr K, Hachem R, Papanicolau G et al. Retrospective study of concomitant use of caspofungin with cyclosporin A (CsA) in patients treated during marketed use. Blood 2003; 102: 471a (abstr. 1717).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sanz-Rodriguez, C., Lopez-Duarte, M., Jurado, M. et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34, 13–20 (2004). https://doi.org/10.1038/sj.bmt.1704516
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704516
Keywords
This article is cited by
-
Strategien bei Versagen einer antimykotischen Therapie auf Intensivstation
Der Anaesthesist (2015)
-
Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins
Current Fungal Infection Reports (2012)
-
Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT
Bone Marrow Transplantation (2010)
-
Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update
Mycopathologia (2009)
-
Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection
Bone Marrow Transplantation (2007)